Treatment duration as a surrogate endpoint to evaluate the efficacy of crizotinib in sequential therapy for patients with advanced ALK‐positive non‐small cell lung cancer: A retrospective, real‐world study

OBJECTIVES: Crizotinib has demonstrated good efficacy in patients with anaplastic lymphoma kinase (ALK)‐positive non‐small cell lung cancer (NSCLC). Continuing crizotinib therapy beyond progressive disease (CBPD) can achieve ongoing survival benefit in real‐world clinical practice. In terms of survi...

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Guangjian, Ma, Di, Xu, Haiyan, Yang, Lu, Li, Junling, Xing, Puyuan, Hao, Xuezhi, Wang, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6792485/
https://www.ncbi.nlm.nih.gov/pubmed/31407528
http://dx.doi.org/10.1002/cam4.2420

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6792485/
https://www.ncbi.nlm.nih.gov/pubmed/31407528
http://dx.doi.org/10.1002/cam4.2420

Ejemplares similares